Chia Tai Enterprises International Limited (03839.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 13Aug 18Aug 21Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

10.1x

Market Cap

HKD 2.20B

MomentumView details →

1D Return

−1.03%

YTD Return

+19.79%

RSI (14)

46.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

10.1x

Market Cap

HKD 2.20B

RSI (14)

46.6

MomentumView details →

1D Return

−1.03%

YTD Return

+19.79%

ProfitabilityView details →

Gross Margin

16.60%

Net Margin

5.76%

EBITDA Margin

8.17%

ROE (TTM)

8.32%

ROA (TTM)

4.84%

Asset Turnover

0.86x

GrowthView details →

Revenue YoY

−18.94%

EPS YoY

−6.66%

FCF YoY

—

Revenue CAGR 3Y

+49.93%

EPS CAGR 3Y

+258.77%

EBITDA YoY

−12.16%

EarningsView details →

EPS (Actual)

HKD 0.17

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.26x

Current Ratio

1.60x

Quick Ratio

1.36x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

424.03M

Net Income (TTM)

24.44M

Op. CF (TTM)

0.00

Latest newsMore news →

Zhengda Biotech announced its interim results for the six months ended June 2026, with revenue of $211 million, down 34.6% year-on-year, and net profit of $9.423 million, down 44.7% year-on-year.24d ago

Similar companies

Avadel Pharmaceuticals plcAVDL Jacobson Pharma Corporation Limited02633.HK Perrigo Company plcPRGO VISEN Pharmaceuticals02561.HK 圣达生物603079.SH Hua Medicine (Shanghai) Ltd.02552.HK Find similar companies →

Latest newsMore news →

Zhengda Biotech announced its interim results for the six months ended June 2026, with revenue of $211 million, down 34.6% year-on-year, and net profit of $9.423 million, down 44.7% year-on-year.24d ago